We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

89 hedge funds and large institutions have $229M invested in Cue Biopharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.07% less ownership

Funds ownership: 2.13% → 2.06% (-0.07%)

5% less capital invested

Capital invested by funds: $241M → $229M (-$12M)

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

8% less funds holding

Funds holding: 97 → 89 (-8)

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

76% less call options, than puts

Call options by funds: $732K | Put options by funds: $3.06M

Holders
89
Holders Change
-8
Holders Change %
-8.25%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
31
Reduced
33
Closed
14
Calls
$732K
Puts
$3.06M
Net Calls
-$2.33M
Net Calls Change
+$35K

Top Buyers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
+$8.69M
2
AR
Advisory Research
Illinois
+$3.51M
3
NCM
Nantahala Capital Management
Connecticut
+$2.71M
4
SMH
Sanders Morris Harris
Texas
+$2.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.51M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$5.66M
2
PM
Prosight Management
Texas
-$4.8M
3
WP
Woodline Partners
California
-$4.22M
4
Millennium Management
Millennium Management
New York
-$3.9M
5
Morgan Stanley
Morgan Stanley
New York
-$3.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
BL
26
Bleichroeder LP
New York
$915K – – –
Citigroup
27
Citigroup
New York
$906K +$936K +2,275 +1,138%
SPC
28
Sigma Planning Corp
Michigan
$892K +$20.6K +50 +2%
Stifel Financial
29
Stifel Financial
Missouri
$804K – – –
Rafferty Asset Management
30
Rafferty Asset Management
New York
$724K +$634K +1,540 +351%
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$714K -$72K -175 -8%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$689K +$456K +1,107 +143%
Swiss National Bank
33
Swiss National Bank
Switzerland
$676K +$27.6K +67 +4%
UBS Group
34
UBS Group
Switzerland
$640K +$410K +996 +133%
RCG
35
Rock Creek Group
District of Columbia
$610K -$686K -1,667 -50%
Bank of America
36
Bank of America
North Carolina
$542K +$219K +533 +56%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$541K – – –
AC
38
Apogem Capital
New York
$521K -$183K -445 -24%
CAM
39
ClariVest Asset Management
California
$490K +$180K +437 +48%
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$483K -$318K -773 -37%
PM
41
Precept Management
Texas
$427K -$1.58M -3,833 -77%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$404K -$25.1K -61 -5%
AllianceBernstein
43
AllianceBernstein
Tennessee
$349K -$45.3K -110 -10%
Deutsche Bank
44
Deutsche Bank
Germany
$348K -$126K -305 -24%
Russell Investments Group
45
Russell Investments Group
United Kingdom
$333K -$322K -783 -46%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$310K – – –
TI
47
Trexquant Investment
Connecticut
$309K +$109K +266 +46%
Barclays
48
Barclays
United Kingdom
$302K +$156K +379 +85%
CS
49
Credit Suisse
Switzerland
$280K -$446K -1,084 -59%
WHG
50
Westwood Holdings Group
Texas
$275K – – –
1
2
3 4 5

CUE Hedge Fund Activity: Q1 2021 in Review

89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2021, worth a combined $229M — down 5% from $241M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CUE and 6 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 31 added.

The largest buyer was Corriente Advisors, adding an estimated $8.69M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $5.66M sold.

  • 89 institutional investors held Cue Biopharma (CUE) as of Q1 2021, down from 97 in Q4 2020.
  • Funds reported $229M of Cue Biopharma stock for Q1 2021, down 5% quarter-over-quarter.
  • 6 funds opened new Cue Biopharma positions in Q1 2021 and 14 closed out, a net change of -8 holders.
  • The largest Cue Biopharma buyer in Q1 2021 was Corriente Advisors, an estimated $8.69M added.
  • The largest Cue Biopharma seller in Q1 2021 was Avoro Capital Advisors, an estimated $5.66M sold.

Based on aggregated 13F filings for Q1 2021.